Kenya has the seventh-largest number of people living with HIV in the world, at around 1.4 million, according to World Health ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Fiji health authorities are scrambling to stem an outbreak of HIV, as growing meth use and alarming needle-sharing trends accelerate the spread of the virus.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...